Rocket Doctor AI

Rocket Doctor AI Forward P/E

Delisted

The Forward P/E Ratio of Rocket Doctor AI (TRUE.CN) as of Nov 15, 2026 is -9.30. In the previous year, Forward P/E Ratio was -18.88 — a change of -50.72% (higher).

Forward P/E

-9.30

YoY

-50.72%

Last updated:

Forward P/E Ratio of Rocket Doctor AI is 2024 -9.30 . Forward P/E Ratio of Rocket Doctor AI was 2023 -18.88 . It decreases by -50.72% higher compared to the previous year.

The Rocket Doctor AI Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2017
-728.29 CAD
Jan 1, 2018
-1,002.57 CAD
Jan 1, 2019
-23.40 CAD
Jan 1, 2020
-24.17 CAD
Jan 1, 2021
-5.07 CAD
Jan 1, 2022
-18.51 CAD
Jan 1, 2023
-18.88 CAD
Jan 1, 2024
-9.30 CAD
The Rocket Doctor AI Forward P/E history
YEARForward P/EYoY
-9.30-50.72%
-18.88+2.00%
-18.51+265.15%
-5.07-79.02%
-24.17+3.29%
-23.40-97.67%
-1,002.57+37.66%
-728.29—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Rocket Doctor AI Stock analysis

What does Rocket Doctor AI do? Treatment.com AI Inc generates revenue through its Treatment Digital Health App, a symptom assessment tool developed by a global team of doctors and engineers. The app provides predictive health insights using disease rate estimates, geographic variation data, and medical research, targeting patients and caregivers seeking informed health decisions. The company also offers medical education solutions and clinical advisor services, serving healthcare professionals and institutions globally. Revenue streams include subscriptions for app access and tailored medical education programs. The Treatment Digital Health App is designed for widespread use, offering advanced medical knowledge access to users worldwide. Medical clinic solutions are integrated into the platform, supporting healthcare providers in decision-making. Clinical advisor services leverage the AI platform to assist clinics and institutions with specialized medical guidance. These offerings are marketed to healthcare consumers, clinics, and educational institutions as part of the company's global healthcare technology strategy. Treatment.com AI Inc's business model focuses on AI-driven health solutions, with the Treatment Digital Health App as its primary product. The app's predictive health assessments are updated regularly by medical professionals, ensuring relevance and accuracy. The company monetizes through direct consumer subscriptions and B2B partnerships with medical clinics and educational providers, emphasizing global accessibility and evidence-based medical insights. Rocket Doctor AI is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Rocket Doctor AI stock

Forward P/E Ratio of Rocket Doctor AI is -9.30 in 2024.

Forward P/E Ratio of Rocket Doctor AI changed from -18.88 to -9.30, representing a -50.72% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Rocket Doctor AI since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Rocket Doctor AI with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Rocket Doctor AI

All Key Metrics — Rocket Doctor AI